Cumberland Pharmaceuticals — Q3 2026 Earnings Summary

Cumberland Pharmaceuticals reported a net income of $77.8 million for the third quarter of 2026, driven primarily by an $81.1 million gain from its strategic transaction with Apotex Health which closed on July 1, 2026. Following the transaction, the company has shifted its focus to a development-only model, retaining $80.6 million in cash and cash equivalents while integrating its commercial brands into Apotex's U.S. business. Cumberland announced plans to submit a New Drug Application to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, supported by positive Phase 2 trial data showing improved left ventricular ejection fraction. Additionally, the company released top-line results from a Phase 2a trial for ifetroban in systemic sclerosis, noting the drug was well-tolerated with no treatment-related serious adverse events.